“On track” is reassuring, but what would make the update useful? Most sponsors have sat through a status call where every indicator was green and the CRO was confident, and they still left the meeting not entirely certain about the next milestone. In my experience, that unease says less about the CRO than about the shape of the update. A status report is built to answer “how are we doing?”, and a sponsor approaching last patient in or database lock usually needs an answer to a different question: what should we be ready for?
Consider a Phase 2 study reporting 42 of 60 sites activated and enrollment at 88% of plan in month nine. Both figures can be accurate, and the forecast can still rest on assumptions that have shifted since the plan was set: a screen failure rate that has crept from 30% to 38%, or two high-enrolling sites approaching their contracted cap. Neither change turns the dashboard red, yet either one can move last patient in by roughly two months. For most sponsors, that is the date that matters, because database lock, the topline readout, and often the next financing conversation are all sequenced behind it.
At ABRA Clinical Consulting, these are the four questions we help sponsors bring to the CRO before a governance meeting:
On track against which assumptions (enrollment per site per month, screen failure rate, activation dates)?
What has changed since the last report, even if the topline has not moved?
What needs a decision from us, and by when?
What could alter the forecast over the next 90 days, and how early would we see it?
None of these questions signals doubt about the CRO team. The project leaders I have most admired welcomed them, because a sponsor who understands the assumptions can make a timely call on a protocol amendment, a rescue site, or a budget change. Reassurance tells us where we stand today, and visibility that supports decisions tells us what we will need to do next. “On track” remains a good thing to hear, and with four more questions, it becomes something we can act on together.
